[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-metastases-from-solid-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-metastases-from-solid-tumors":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100601630","development-of-innovative-preclinical-ex-vivo-models-for-the-study-of-sarcomas-and-metastases-from-solid-tumors-100601630",false,"NCT07112989","Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors","PREMOD","Inclusion Criteria:\n\n* Patients (male or female) diagnosed with sarcoma or with bone or lung metastases from solid tumors\n* Age between 0 and 85 years\n* Availability of sufficient and adequate biological material (tumor tissue and\u002For blood)\n* Signed informed consent for biobanking (BIOTUM)\n* Signed informed consent for use of tissue and blood samples in this study\n\nExclusion Criteria:\n\n* Diagnosis other than sarcoma or metastases from solid tumors\n* Missing signed informed consent(s)","ALL","85 Years",{"count":19,"type":20},125,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn how tumor tissue and blood samples from patients with sarcomas or metastases can be used to create laboratory models that help researchers study cancer behavior and test new treatments. Participants diagnosed with sarcoma or with bone or lung metastases from solid tumors will donate leftover tumor tissue and blood collected during their regular medical care. These samples will be used in the lab to build 3D models of the tumor, test drugs, and identify genetic and molecular markers. No treatments or procedures will be given as part of the study.",[24,25,26],"Bone and Soft Tissue Tumors","Bone Metastases From Solid Tumors","Lung Metastases",[28,29,30,31],"Sarcomas","Bone metastases","Lung metastases","Preclinical models","RECRUITING","2025-08-01",{"date":35,"type":36},"2025-08-08","ACTUAL",{"date":38,"type":36},"2024-09-23",{"date":40,"type":20},"2031-09-23",{"name":42,"class":43},"Istituto Ortopedico Rizzoli","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100521436","phase-1-safety-study-for-a-gamma-delta-t-cell-product-used-with-low-dose-radiotherapy-in-patients-with-locally-advanced-or-metastatic-nsclc-or-solid-tumors-with-bone-metastases-100521436","NCT06069570","Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases","Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer or Solid Tumors With Bone Metastases","Inclusion Criteria:\n\n* Signed and dated informed consent form.\n* Male or female, \\> 18 years old.\n* Minimum body weight of 50 kilograms (kg).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically or cytologically confirmed locally advanced or metastatic NSCLC or locally advanced or metastatic solid tumor with bone metastasis\n* Progressed on SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors (NSCLC), and are not a candidate for further standard anti-neoplastic therapy and\u002For have exhibited intolerance to and\u002For declined clinically applicable salvage therapies, and\u002For have declined therapy.\n* Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriate target-directed molecular therapy.\n* At least one measurable target lesion based on RECIST v1.1 confirmed by radiological imaging. Participants with isolated bone metastases are eligible for enrollment are not required to have measurable disease\n* All toxicity associated with previous treatments are recovered to CTCAE grade of ≤1, except for continuing alopecia.\n* Adequate hematopoietic, hepatic and renal function\n* Agree to adequate contraception for up to 120 days after the last dose of study drug.\n* Negative serum pregnancy test for women of childbearing potential\n* All primary and metastatic disease sites are amenable to LDRT\n* For solid tumors with bone metastases subjects (Part 2 Cohort B): receiving zoledronic acid for solid tumors with bone metastases\n\nExclusion Criteria:\n\n* Chemotherapy, investigational, and\u002For check-point inhibitor therapy within the 30 days prior to study Day 1.\n* Major surgery, except for vascular access placement, within the 30 days prior to study Day 1.\n* Active autoimmune disease requiring immunosuppressive therapy.\n* Infection requiring systemic treatment within 30 days prior to study Day 1.\n* History of peritoneal effusion (ascites), pericardial, or pleural effusions\u002Fnodules.\n* Uncontrolled hypertension, history of arrhythmia including atrial fibrillation, unstable angina, decompensated congestive heart failure, cardiac ejection fraction ≤ 50%, myocardial infarction, or marked baseline prolonged QT\u002FQTc intervals.\n* Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C detection.\n* Participation in the treatment portion of a clinical trial or completed a clinical trial within the 30 days prior to the first dose of KB-GDT-01.\n* Presence of any condition that may, in the opinion of the Investigator, render the patient inappropriate from participating in the study.\n* Breastfeeding or pregnant female, or patient is expecting to conceive or father children during the study.\n* Allergy or intolerance to any of the study product ingredients or excipients.\n* Live vaccines administered within 30 days prior to study Day 1.\n* Individuals lacking capacity to consent for themselves.\n* Superior vena cava obstruction\n* Prior radiation therapy to a selected LDRT treatment site \\\u003C\u002F= 30 days prior to Day 1.","18 Years",{"count":54,"type":20},48,"INTERVENTIONAL",[57],"PHASE1","This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.",[60,25],"Carcinoma, Non-Small-Cell Lung Cancer","2025-03-03",{"date":63,"type":36},"2025-03-05",{"date":65,"type":36},"2023-11-07",{"date":67,"type":20},"2026-10",{"name":69,"class":70},"Kiromic BioPharma Inc.","INDUSTRY",5]